These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 17441371)

  • 21. Intracardiac echocardiography guidance during percutaneous transluminal septal myocardial ablation in patients with obstructive hypertrophic cardiomyopathy.
    Pedone C; Vijayakumar M; Ligthart JM; Valgimigli M; Biagini E; De Jong N; Serruys PW; Ten Cate FJ
    Int J Cardiovasc Intervent; 2005; 7(3):134-7. PubMed ID: 16243734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Percutaneous transluminal septal artery ablation using polyvinyl alcohol foam particles for septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy: acute and 3-year outcomes.
    Gross CM; Schulz-Menger J; Krämer J; Siegel I; Pilz B; Waigand J; Friedrich MG; Uhlich F; Dietz R
    J Endovasc Ther; 2004 Dec; 11(6):705-11. PubMed ID: 15615561
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy.
    Seggewiss H; Rigopoulos A; Welge D; Ziemssen P; Faber L
    Clin Res Cardiol; 2007 Dec; 96(12):856-63. PubMed ID: 17891517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Percutaneous transluminal septal myocardial ablation in patients with hypertrophic obstructive cardiomyopathy.
    Jiang T; Wu X; Jia C; Zhang Y; Lü Q
    Chin Med J (Engl); 2002 Jan; 115(1):26-30. PubMed ID: 11930652
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progressive decrease of outflow gradient and septum thickness after percutaneous alcoholization of the interventricular septum in hypertrophic obstructive cardiomyopathy.
    Airoldi F; Di Mario C; Catanoso A; Dharmadhikari A; Tzifos V; Anzuini A; Carlino M; Briguori C; Montorfano M; Vaghetti M; Tolaro S; Colombo A
    Ital Heart J; 2000 Mar; 1(3):200-6. PubMed ID: 10806987
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Percutaneous transluminal septal myocardial ablation in patients with hypertrophic obstructive cardiomyopathy: immediately and middle-term follow-up results].
    Jiang T; Wu X; Jia C
    Zhonghua Nei Ke Za Zhi; 2001 Oct; 40(10):663-5. PubMed ID: 11769718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Long-term outcome of patients with hypertrophic obstructive cardiomyopathy post percutaneous transluminal septal ablation].
    Zheng SW; Shi HY; Dai JJ; Chen H; Wu WH; Qiu XB
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr; 48(4):294-301. PubMed ID: 32370480
    [No Abstract]   [Full Text] [Related]  

  • 28. Percutaneous versus surgical treatment for patients with hypertrophic obstructive cardiomyopathy and enlarged anterior mitral valve leaflets.
    van der Lee C; ten Cate FJ; Geleijnse ML; Kofflard MJ; Pedone C; van Herwerden LA; Biagini E; Vletter WB; Serruys PW
    Circulation; 2005 Jul; 112(4):482-8. PubMed ID: 16027255
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Repeated percutaneous transluminal septal myocardial ablation leads to reduction of left ventricular outflow-tract pressure gradient in hypertrophic obstructive cardiomyopathy: a case report].
    Takeda M; Mori T; Ohashi Y; Ichikawa S; Terashima M; Ejiri J; Awano K
    J Cardiol; 2006 Jun; 47(6):313-21. PubMed ID: 16800375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Percutaneous transluminal septal myocardial ablation in drug-resistant hypertrophic obstructive cardiomyopathy: 18-month follow-up results.
    Oomman A; Ramachandran P; Subramanyan K; Kalarickal MS; Osman MN
    J Invasive Cardiol; 2001 Jul; 13(7):526-30. PubMed ID: 11435640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of septal ablation on regional diastolic dysfunction and diastolic asynchrony in patients with hypertrophic obstructive cardiomyopathy: a follow-up study using speckle tracking echocardiography.
    Chen S; Duan F; Yuan J; Qiao S; Lv X; Hu F; Yang W; Zhang J; Yang Y
    Echocardiography; 2013 May; 30(5):564-71. PubMed ID: 23305549
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Septal ethanol ablation for hypertrophic obstructive cardiomyopathy: early and intermediate results of a Canadian referral centre.
    Bhagwandeen R; Woo A; Ross J; Wigle ED; Rakowski H; Kwinter J; Eriksson MJ; Schwartz L
    Can J Cardiol; 2003 Jul; 19(8):912-7. PubMed ID: 12876612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of percutaneous transluminal septal myocardial ablation for relief of outflow tract obstruction in cardiac amyloidosis: a novel therapeutic target.
    Murphy RT; Ratliff NB; Lever HM; Kapadia SR
    Catheter Cardiovasc Interv; 2006 Oct; 68(4):637-41. PubMed ID: 16969877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world clinical outcomes of percutaneous transluminal septal myocardial ablation for patients with drug-refractory hypertrophic obstructive cardiomyopathy: results from a retrospective multicenter registry of non-high-volume centers.
    Nakamura K; Toba T; Otake H; Kakizaki S; Fujimoto D; Takahashi Y; Fukuyama Y; Kawamori H; Tanaka H; Takaya T; Iwasaki M; Kozuki A; Kawai H; Hayashi T; Shite J; Hirata KI
    Heart Vessels; 2022 Nov; 37(11):1937-1946. PubMed ID: 35641828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Non-drug treatment for hypertrophic obstructive cardiomyopathy in children].
    Zhang X; Li YF; Xie B; Chen JY; Qian MY
    Zhonghua Er Ke Za Zhi; 2011 May; 49(5):381-5. PubMed ID: 21624293
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of Clinical Effects between Percutaneous Transluminal Septal Myocardial Ablation and Modified Morrow Septal Myectomy on Patients with Hypertrophic Cardiomyopathy.
    Guo HC; Li JH; Jiang TY; Ren CW; Dai J; Zhou YJ; Lai YQ
    Chin Med J (Engl); 2018 Mar; 131(5):527-531. PubMed ID: 29483385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy.
    Tsuchikane E; Takeda Y; Kobayashi T; Yachiku K; Nasu K; Kobayashi Y; Matsumoto H; Awata N
    Circ J; 2003 Sep; 67(9):763-7. PubMed ID: 12939552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The biphasic course of changes of left ventricular outflow gradient after alcohol septal ablation for hypertrophic obstructive cardiomyopathy.
    Veselka J; Duchonová R; Procházková S; Homolová I; Pálenícková J; Zemánek D; Pernisová Z; Tesar D
    Kardiol Pol; 2004 Feb; 60(2):133-6; discussion 137. PubMed ID: 15116158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Percutaneous transluminal septal myocardial ablation in the treatment of hypertrophic obstructive cardiomyopathy: short-term study].
    Veselka J; Tesar D; Urbanová T; Telekes P; Honĕk T; Neuwirth J
    Vnitr Lek; 2001 Jul; 47(7):437-43. PubMed ID: 11505713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complications of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy.
    Zhang W; Li Z; Zhang M; Yuan L; Guan R; Hou A; Jin Y; Deng Z
    Chin Med J (Engl); 2002 Sep; 115(9):1283-6. PubMed ID: 12411095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.